Targeting Ferroptosis with Polyphenolic Carbon Dots to Attenuate Myocardial Ischemia-Reperfusion Injury by Reducing Iron Accumulation and Enhancing Antioxidant Defense
Source abstract
Abstract
Despite the widespread application of percutaneous coronary intervention in acute myocardial infarction, one-year mortality and heart failure rates remain unacceptably high, primarily driven by myocardial ischemia-reperfusion (I/R) injury. Ferroptosis, which predominantly occurs during late reperfusion, significantly contributes to adverse outcomes. Here, we rationally designed and synthesized polyphenolic carbon dots derived from resveratrol (Res-CDs) using an alkali-assisted carbonization approach. Res-CDs effectively suppressed ferroptosis by reducing iron accumulation and enhancing antioxidant defense, conferring robust cardioprotection in cellular and rat models of myocardial I/R injury. Mechanistically, Res-CDs activated the Nrf2 pathway, driving nuclear translocation and subsequent upregulation of antioxidant and iron metabolism-related genes. Notably, Res-CDs circumvented the pharmacokinetic limitations of native resveratrol while exhibiting favorable biocompatibility both in vitro and in vivo. Collectively, these findings establish Res-CDs as a promising nanotherapeutic strategy for myocardial I/R injury and underscore the potential of polyphenolic carbon dots in advancing cardiovascular disease treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ferroptosis and cancer prognosis · Carbon and Quantum Dots Applications · Genomics, phytochemicals, and oxidative stress
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Cardiology
China-Japan Union Hospital of Jilin University
Department of Neurology
State Key Laboratory of Rare Earth Resource Utilization and Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, No. 5625 Renmin Street, Changchun 130022, P. R. China
Funding
National Natural Science Foundation of China
References (59)
Show source-provided references
1. 10.1093/eurheartj/ehaf28910.1093/eurheartj/ehaf289 ↗
2. 10.1016/j.jacc.2021.09.00610.1016/j.jacc.2021.09.006 ↗
3. 10.1038/s41420-025-02372-510.1038/s41420-025-02372-5 ↗
4. 10.1038/s41580-023-00648-110.1038/s41580-023-00648-1 ↗
5. 10.1161/CIRCULATIONAHA.122.06025710.1161/CIRCULATIONAHA.122.060257 ↗
6. 10.1155/2021/992968710.1155/2021/9929687 ↗
7. 10.3390/antiox1101015010.3390/antiox11010150 ↗
8. 10.1002/jsfa.1015210.1002/jsfa.10152 ↗
9. 10.3390/ijms22181015210.3390/ijms221810152 ↗
10. 10.3389/fphar.2022.92447310.3389/fphar.2022.924473 ↗
11. 10.1016/j.jnutbio.2022.10924110.1016/j.jnutbio.2022.109241 ↗
12. 10.3390/nu1309309510.3390/nu13093095 ↗
13. 10.1038/s41565-021-01051-710.1038/s41565-021-01051-7 ↗
14. 10.1039/D0SC03246H10.1039/D0SC03246H ↗
15. 10.1002/advs.20251219610.1002/advs.202512196 ↗
16. 10.1016/j.scib.2024.08.01110.1016/j.scib.2024.08.011 ↗
17. 10.1002/adfm.20241840710.1002/adfm.202418407 ↗
18. 10.1021/acs.nanolett.4c0341810.1021/acs.nanolett.4c03418 ↗
19. 10.1038/s41467-025-57531-010.1038/s41467-025-57531-0 ↗
20. 10.1002/adma.20242006810.1002/adma.202420068 ↗
21. 10.1038/s41467-025-57890-810.1038/s41467-025-57890-8 ↗
22. 10.1021/jacs.4c1564610.1021/jacs.4c15646 ↗
23. 10.1002/adma.20250455710.1002/adma.202504557 ↗
24. 10.1096/fj.202503622r10.1096/fj.202503622r ↗
25. 10.1016/j.matt.2025.10208410.1016/j.matt.2025.102084 ↗
26. 10.1038/s41467-025-58513-y10.1038/s41467-025-58513-y ↗
27. 10.1186/s12951-025-03494-910.1186/s12951-025-03494-9 ↗
28. 10.1186/s12951-025-03477-w10.1186/s12951-025-03477-w ↗
29. 10.1002/adma.20241423710.1002/adma.202414237 ↗
30. 10.1161/CIRCULATIONAHA.123.06709710.1161/CIRCULATIONAHA.123.067097 ↗
31. 10.1016/j.phymed.2024.15564910.1016/j.phymed.2024.155649 ↗
32. Huang Y. · Trends Endocrinol. Metab. · 2024 · 35 · 21910.1016/j.tem.2023.10.010 ↗
33. 10.1002/advs.20190131610.1002/advs.201901316 ↗
34. 10.1002/adma.20221077610.1002/adma.202210776 ↗
35. 10.1016/j.carbon.2023.03.03910.1016/j.carbon.2023.03.039 ↗
36. 10.1021/acs.chemrev.5b0000810.1021/acs.chemrev.5b00008 ↗
37. 10.1021/acsomega.5c1276010.1021/acsomega.5c12760 ↗
38. 10.1124/jpet.102.03334010.1124/jpet.102.033340 ↗
39. 10.1016/j.msec.2020.11101610.1016/j.msec.2020.111016 ↗
40. 10.1039/D4SC05280C10.1039/D4SC05280C ↗
41. 10.3390/nano1516127910.3390/nano15161279 ↗
42. 10.3390/c1003006010.3390/c10030060 ↗
43. 10.1016/j.cej.2019.02.07810.1016/j.cej.2019.02.078 ↗
44. 10.1002/wnan.196710.1002/wnan.1967 ↗
45. 10.1002/adhm.20210019610.1002/adhm.202100196 ↗
46. 10.1038/s41580-020-0230-310.1038/s41580-020-0230-3 ↗
47. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
48. 10.7150/thno.5411310.7150/thno.54113 ↗
49. 10.1038/s41580-024-00703-510.1038/s41580-024-00703-5 ↗
50. 10.1038/s41392-024-01969-z10.1038/s41392-024-01969-z ↗
51. 10.1016/j.jnutbio.2026.11025910.1016/j.jnutbio.2026.110259 ↗
52. 10.3389/fcell.2020.58657810.3389/fcell.2020.586578 ↗
53. 10.1002/ptr.833510.1002/ptr.8335 ↗
54. 10.1007/s00210-020-01932-z10.1007/s00210-020-01932-z ↗
55. 10.1021/acsami.2c1111710.1021/acsami.2c11117 ↗
56. 10.1038/srep2561310.1038/srep25613 ↗
57. 10.3390/biom1312169010.3390/biom13121690 ↗
58. 10.1016/j.ijbiomac.2025.14375910.1016/j.ijbiomac.2025.143759 ↗
59. 10.1186/s43044-025-00644-010.1186/s43044-025-00644-0 ↗